肌层浸润性膀胱癌新辅助治疗的现状并文献复习  

Current Status of Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer:A Review of the Literature

作　　者：吕泽轩 程强[2] 卢崯 江彬 高帆 艾青[2] 李宏召[2] Lyu Zexuan;Cheng Qiang;Lu Yin;Jiang Bin;Gao Fan;Ai Qing;Li Hongzhao(Medical School of Nankai University,Tianjin 300071,China;Department of Urology,the Third Medical Center of PLA General Hospital,Beijing 100039,China)

机构地区：[1]南开大学医学院,天津300071 [2]解放军总医院第三医学中心泌尿外科医学部,北京100039

出　　处：《微创泌尿外科杂志》2025年第1期55-63,共9页Journal of Minimally Invasive Urology

基　　金：国家重点研发计划(2023YFC2507006、2022YFC3602900)。

摘　　要：肌层浸润性膀胱癌(MIBC)作为一种高危的膀胱癌亚型,预后较差,且目前治疗效果有限。新辅助治疗在MIBC的治疗中扮演着重要角色,尤其在减少术后复发和提高生存率方面展现出良好效果。本文旨在查阅大量文献总结分析目前常用新辅助治疗方案的疗效、安全性及预后等现状,并且讨论当下新辅助治疗所面临的难题与挑战,即受益群体选择、最佳疗程选择以及个体化治疗的应用效果,为临床选择提供有价值的参考。Muscle-invasive bladder cancer(MIBC)is a high-risk subtype of bladder cancer with a poor progno-sis,and current treatment options remain limited.Neoadjuvant therapy plays a crucial role in the management of MIBC,particularly in reducing postoperative recurrence and improving survival rates.This review aims to summarize and analyze the efficacy,safety,and prognosis of commonly used neoadjuvant treatment regimens based on extensive literature.Additionally,it discusses the challenges faced by current neoadjuvant therapies,including the selection of appropriate patient populations,optimal treatment duration,and the effectiveness of personalized treatment approach-es,providing valuable insights for clinical decision-making.

关 键 词：新辅助治疗 肌层浸润性膀胱癌 化疗与免疫治疗 治疗难题 

分 类 号：R737.14[医药卫生—肿瘤]